Investigational drugs targeting FLT3 for leukemia

Celalettin Ustun, David L. DeRemer, Anand P. Jillella, Kapil N. Bhalla

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

FMS-like tyrosine kinase-3 (FLT3) is a member of the class III membrane receptor tyrosine kinase family and is important in survival, proliferation and differentiation of hematopoietic cells. FLT3 is mutated in ∼ 30% of acute myelogenous leukemia patients. These mutations involve internal tandem duplications in the juxtamembrane domain of the receptor and tyrosine kinase point mutations in the activation loop. Over the past decade, due to the incidence and poor prognosis associated with FLT3, numerous agents have been developed to directly inhibit the activity of wild type and mutated FLT3. In this review, we focus on the preclinical data demonstrating in vitro activity, inhibition of downstream signaling pathways and potential synergy with traditional chemotherapeutic agents. Also, early clinical trial data specifically focusing on drug toxicity, clinical efficacy and future directions of FLT3-directed anticancer therapy are discussed.

Original languageEnglish (US)
Pages (from-to)1445-1456
Number of pages12
JournalExpert Opinion on Investigational Drugs
Volume18
Issue number10
DOIs
StatePublished - Oct 1 2009
Externally publishedYes

Fingerprint

Investigational Drugs
Drug Delivery Systems
Protein-Tyrosine Kinases
Leukemia
Receptor Protein-Tyrosine Kinases
Drug-Related Side Effects and Adverse Reactions
Point Mutation
Acute Myeloid Leukemia
Cell Differentiation
Clinical Trials
Mutation
Membranes
Survival
Incidence

Keywords

  • Acute myelogenous leukemia
  • Drug development
  • FLT3
  • Internal tandem duplications
  • Tyrosine kinase domain

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Investigational drugs targeting FLT3 for leukemia. / Ustun, Celalettin; DeRemer, David L.; Jillella, Anand P.; Bhalla, Kapil N.

In: Expert Opinion on Investigational Drugs, Vol. 18, No. 10, 01.10.2009, p. 1445-1456.

Research output: Contribution to journalReview article

Ustun, Celalettin ; DeRemer, David L. ; Jillella, Anand P. ; Bhalla, Kapil N. / Investigational drugs targeting FLT3 for leukemia. In: Expert Opinion on Investigational Drugs. 2009 ; Vol. 18, No. 10. pp. 1445-1456.
@article{d290b669613c40459f6addcf5a6233be,
title = "Investigational drugs targeting FLT3 for leukemia",
abstract = "FMS-like tyrosine kinase-3 (FLT3) is a member of the class III membrane receptor tyrosine kinase family and is important in survival, proliferation and differentiation of hematopoietic cells. FLT3 is mutated in ∼ 30{\%} of acute myelogenous leukemia patients. These mutations involve internal tandem duplications in the juxtamembrane domain of the receptor and tyrosine kinase point mutations in the activation loop. Over the past decade, due to the incidence and poor prognosis associated with FLT3, numerous agents have been developed to directly inhibit the activity of wild type and mutated FLT3. In this review, we focus on the preclinical data demonstrating in vitro activity, inhibition of downstream signaling pathways and potential synergy with traditional chemotherapeutic agents. Also, early clinical trial data specifically focusing on drug toxicity, clinical efficacy and future directions of FLT3-directed anticancer therapy are discussed.",
keywords = "Acute myelogenous leukemia, Drug development, FLT3, Internal tandem duplications, Tyrosine kinase domain",
author = "Celalettin Ustun and DeRemer, {David L.} and Jillella, {Anand P.} and Bhalla, {Kapil N.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1517/13543780903179278",
language = "English (US)",
volume = "18",
pages = "1445--1456",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Investigational drugs targeting FLT3 for leukemia

AU - Ustun, Celalettin

AU - DeRemer, David L.

AU - Jillella, Anand P.

AU - Bhalla, Kapil N.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - FMS-like tyrosine kinase-3 (FLT3) is a member of the class III membrane receptor tyrosine kinase family and is important in survival, proliferation and differentiation of hematopoietic cells. FLT3 is mutated in ∼ 30% of acute myelogenous leukemia patients. These mutations involve internal tandem duplications in the juxtamembrane domain of the receptor and tyrosine kinase point mutations in the activation loop. Over the past decade, due to the incidence and poor prognosis associated with FLT3, numerous agents have been developed to directly inhibit the activity of wild type and mutated FLT3. In this review, we focus on the preclinical data demonstrating in vitro activity, inhibition of downstream signaling pathways and potential synergy with traditional chemotherapeutic agents. Also, early clinical trial data specifically focusing on drug toxicity, clinical efficacy and future directions of FLT3-directed anticancer therapy are discussed.

AB - FMS-like tyrosine kinase-3 (FLT3) is a member of the class III membrane receptor tyrosine kinase family and is important in survival, proliferation and differentiation of hematopoietic cells. FLT3 is mutated in ∼ 30% of acute myelogenous leukemia patients. These mutations involve internal tandem duplications in the juxtamembrane domain of the receptor and tyrosine kinase point mutations in the activation loop. Over the past decade, due to the incidence and poor prognosis associated with FLT3, numerous agents have been developed to directly inhibit the activity of wild type and mutated FLT3. In this review, we focus on the preclinical data demonstrating in vitro activity, inhibition of downstream signaling pathways and potential synergy with traditional chemotherapeutic agents. Also, early clinical trial data specifically focusing on drug toxicity, clinical efficacy and future directions of FLT3-directed anticancer therapy are discussed.

KW - Acute myelogenous leukemia

KW - Drug development

KW - FLT3

KW - Internal tandem duplications

KW - Tyrosine kinase domain

UR - http://www.scopus.com/inward/record.url?scp=70349305452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349305452&partnerID=8YFLogxK

U2 - 10.1517/13543780903179278

DO - 10.1517/13543780903179278

M3 - Review article

C2 - 19671038

AN - SCOPUS:70349305452

VL - 18

SP - 1445

EP - 1456

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 10

ER -